Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/26
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/26
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/27/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILPRNewsWire • 02/12/26
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyNewsfile Corp • 01/20/26
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOncoGlobeNewsWire • 01/06/26
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/25
Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)GlobeNewsWire • 09/10/25
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/25
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in ChinaGlobeNewsWire • 07/31/25
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsGlobeNewsWire • 07/02/25
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should KnowZacks Investment Research • 06/20/25
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a BetZacks Investment Research • 06/16/25
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramGlobeNewsWire • 06/11/25
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceZacks Investment Research • 06/04/25
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerGlobeNewsWire • 06/02/25
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/29/25
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeZacks Investment Research • 05/29/25
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessSeeking Alpha • 05/25/25
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoGlobeNewsWire • 05/23/25
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025GlobeNewsWire • 05/22/25